Reductil 15 MG 28 CAPSULES Group: Human Imported Drug Subgroup: İEGM All Pharmaceutical company Abb

Reductil 15 MG 28 CAPSULES Group: Human Imported Drug Subgroup: İEGM All Pharmaceutical company Abbott Laboratories Active Ingredient: Sibutramine ATC Code: A08AA10 ATC Description: Sibutramine Public Code: A06574 Barcode: 8699548152764 Patent: Original Price: 89.06 AUD Recipe Type NORMAL RECIPES postpartum depression Agent Code: - Available: Only your medicine from the pharmacy to buy! Budget Co-Value Code: - Physical Properties: white, solid Therapeutic Categories: Antidepressant Condition: Good are sold in pharmacies.
As excipients, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, gelatine, postpartum depression sodium lauryl sulfate, shellac, polydimethyl siloxane, soya lecithin (E 322), indigo carmine postpartum depression (E 132), titanium dioxide (E 171), black iron oxide (E 172) contains. Pharmaceutical Form
Sibutramine active therapeutic effects mainly through the secondary and primary amine metabolites (metabolite 1 and metabolite 2) shows. These noradrenaline, serotonin (5-hydroxytryptamine, 5-HT) and dopamine reuptake inhibitors. Sibutramine postpartum depression treated from patients plasma samples noradrenaline (73%) and serotonin (54%) reuptake postpartum depression significant inhibition caused postpartum depression the dopamine re-uptake inhibition (16%) was not significant. Sibutramine and its metabolites, what makes monoamine release agents, postpartum depression nor are inhibitors of monoamine oxidase. Serotonin (5-HT 1, 5-HT 1A, 5-HT 1B, 5-HT 2A, 5-HT 2C), adrenergic (β 1, β 2, β 3, α 1, α 2), dopaminergic (D 1 -like and D 2-like), postpartum depression muscarinic, postpartum depression histaminergic (H 1), such as benzodiazepine and NMDA receptors have no affinity for neurotransmitter receptors. postpartum depression Pharmacokinetic properties
Absorption Sibutramine gastrointestinal tract rapidly absorbed (T max of 1.2 hours) and liver extensive first pass metabolism through the pharmacologically active metabolites, M1 (mono-desmethyl) and M2 (di-desmethyl) postpartum depression are referred to. Peak plasma levels (C max) a single oral 20 mg dose of sibutramine hydrochloride monohydrate is reached after 1.2 hours. Half-life of 1.1 hours the title compound. Pharmacologically active metabolites M1 and M2 C max reached in three hours, and elimination half-lives of 14 and 16 hours, respectively.
Metabolism Sibutramine the cytochrome P450 (3A4) mainly in the liver isoenzyme and desmethyl metabolites M1 and M2 to metabolised. These active metabolites are metabolized by hydroxylation and conjugation to pharmacologically inactive metabolites (M5 and M6) becomes. Marked Sibutramine following oral administration in plasma all marked peak agents, postpartum depression changed sibutramine (3%), M1 (6%), M2 (12%), M5 (52%) and M6 (27%) forms. Linear kinetics over the dose range 10 to 30 mg is shown in elimination half-life was not dose-dependent changes, but dose-dependent increases in plasma concentrations occur. Given repeated postpartum depression dose, steady-state concentrations of metabolites M1 and M2, about 2 to 4 days is achieved by a rigid unit.
The pharmacokinetics of sibutramine and its metabolites in obese people, are similar to those of normal-weight people. So far, very limited data obtained in men and women of the clinically important pharmacokinetic differences found did not provide evidence. In healthy elderly (mean 70 years) observed pharmacokinetic profile postpartum depression is similar to that seen in healthy young men. In patients postpartum depression with moderate hepatic impairment, after a single postpartum depression dose of the active metabolites of sibutramine bioavailability is 24% higher.
Breakthrough: Hepatic metabolism of sibutramine and active metabolites M1 and M2 is the major route of elimination. Other (inactive) metabolites are primarily excreted in urine; urine: faeces ratio 10:1. Indications
Body mass index (BMI) 30 kg / m 2, or body mass index 27 kg / m 2 in patients with additional risk factors are present (eg, hypertension, diabetes, dyslipidemia, etc.) is recommended. Contraindications
Sibutramine in the following cases contraindicated: sibutramine hydrochloride monohydrate or composition of the product in the other a substance known hypersensitivity to any major eating disorder story or the presence of simultaneous monoamine oxidase postpartum depression inhibitors (MAOIs) use (sibutramine before starting treatment with at least two weeks before the MAO should be cut off) centrally acting other The concurrent use of weight loss drugs presence in patients with anorexia nervosa. Warnings / Precautions
Blood Pressure and Heart Rate: heart rate with sibutramine treatment and / or there is a link between the increase in blood pressure. Therefore, before the start of treatment and during treatment postpartum depression with sibutramine blood pressure and heart rate of the patient should be monitored at regular intervals. Sustained and clinically significant k